Voltaren makers face legal action over arthritis-branded gel

ACCC says legal case resembles $6 milllion action on Nurofen specific branding

The makers of Voltaren (diclofenac) are facing legal action for charging more for an osteoarthritis-specific topical gel that has the same ingredients as the standard Voltaren gel.


The Australian Competition and Consumer Commission (ACCC) announced on Wednesday that it was starting legal proceedings in the Federal Court against GSK Consumer Healthcare, a joint venture between GlaxoSmithKline and Novartis.

The ACCC alleges that Voltaren Osteo Gel and Emulgel contain the same active ingredient, diclofenac diethylammonium gel 11.6mg/g, but have been branded as substantially